ADAPY Adaptimmune Therapeutics Plc - ADR

$ADAPY Strong approved finish and strong day closing at the highs after 46% rocket yesterday. Continuation tomorrow.

$ADAPY Absolutely bonkers swing of 3,800% intraday. Let us hope we can very soon kiss this ticker our final goodbyes.

$ADAPY ESMO is on October 23rd in Madrid there is tons about cell therapy if you looked into the abstracts.

$ADAPY ok I talked to our MM. He said normally they exchange a raise in SP for sexual favors but he believes he can get BK to continue to do it for free 🤷‍♂️

$ADAPY Putting it all together, adapy has established exactly what the market demanded from them; an allogeneic derived UMCB (albeit inactive, and with only one knock-in, but with the ability to knock-in their entire IP estate on a as needed basis).. The same tumor types indicated by the now divested, autologus assets can now be exploited at SCALE with added features to ecroach the CAR T market due to the ability to target surface antigens CD70 and mesothelin thanks to TRuC or HiTs knock-ins!! Time to get this thing SOLD or at minimum a BIG PHARMA partnership!!!

$ADAPY So much negotiating power/leverage that adap brings to the table. Not much has been said about their ability to encroach the CAR T space using HiTs (targeting surace antigen mesothelin); not just as IP holders, but the PRE clinical data's already validated per their website and independent journals:

$ADAPY Cont'd from last post: PRAME's expressed HIGHLY in Melanoma so this is undoubtedly the target for CCTI (TILs have outstanding success) Why would adapy "retain" IP rights with TILs? Because they will continue to work with PRAME

$ADAPY biotech reverse mergers up to 36 so far this year compared to 4 last year. Published yesterday

$ADAPY Thanks to all of you technical wizards...I've learn more on message boards than four years of college about the drug development/regulatory processes. I appreciate mgmt for not panicking and sell the company short despite the pressures from shareholders. I've maintained that mgmts are working diligently to increase value and time may prove that. The naysayers believe that every biotech will be a winner..investing is a balance of risk/reward and we're in a sector thats the epitome of that. Pioneering biotechs have significant hidden value..as our more esteemed posters have noted. Sometimes, the processes from start to finish is more valuable than the drug itself...and it seems that our adapy has some elements of that. We may be sitting on something much more valuable than any realize...if so, mgmt deserve some kudos for seeing it through, taking their time, getting every penny for SH...thats the hallmarks of good mgmt. I enjoy the technical read guys.

$ADAPY not only did we break out Wednesday but more importantly we gave none if it back. Primed for continuation next week 👍🏼

$ADAPY have a good weekend yall !! Monday could be the day ! Or Tuesday ! Weds ! Thur fri!! Lol ! Drink some whisky 🥃 it helps !

$ADAPY The "no updates" compliance paperwork filed today successfully checked the box to keep the entity clean, and the order book is responding exactly how a pre-payout shell should. Sit back, ignore the daily micro-fluctuations, and let the clock run out toward the December finale

$ADAPY very high high volume almost 10x the avg!! Bid-ask spread is large. .028 x .0393. That’s crazy on a penny stock. Something must be brewing!!!

$ADAPY even though we had almost 500 K in volume today, no large blocks, no medium-size blocks, just small blocks sold. What’s that tell you? The proof is in the pudding

$ADAPY bid to ask is a 95% gap at close (~50% from the actual close price), a nearly 250,000 share block going through today. We’re there…

$ADAPY This is an event-driven stock, where its price is likely only primarily to be influenced by the possibility of a catalyst or major news event, rather than by ordinary day-to-day trading. Given the thin trading and wide spreads, normal price-discovery assumptions simply cannot reliably apply on most days.

$ADAPY Despite what we already knew about the usefulness of their cutting-edge biomedical technologies and the many patients in need of their potentially life-saving therapies, the market is only now beginning to recognize their commercial value.

$ADAPY So the company $30 mill. cash balance is earning around 5%, the $1.5 million interest, is more than enough to pay the eight remaining employees until the end game....and I believe we'll get an additional $5 mill by YE. Waiting is so bad after all.

$ADAPY These latest observations are interesting; I’ve read them carefully. Two things, dear US_Bull: 1. Could you raise the target a little bit? Come on! ... 2. I hope the "Caribbean plan" hasn't been abandoned ... Warm regards.

$ADAPY Still following MB. Hoping for the best for all the longs. Tried to buy a small position and was paying the ask,but didn't fill. Tomorrow.